Table 1.
Details for influenza A(H1N1)pdm09 (n = 2272) and influenza B cases (n = 2901) and controls (n = 1650) included in the 2015/16 season influenza vaccine effectiveness analysis (week 41/2015‐week 19/2016), I‐MOVE/I‐MOVE+ multicentre case‐control study
| Variables | Number of test‐negative controls a/total n (%) | Number of influenza A(H1N1)pdm09/total n (%) | Number of influenza B cases/total n (%) |
|---|---|---|---|
| Median age (years) | 29.0 | 35.0 | 12.0 |
| Age groups | |||
| 0‐4 | 1437/6004 (23.9) | 365/2268 (16.1) | 536/2894 (18.5) |
| 5‐14 | 739/6004 (12.3) | 321/2268 (14.2) | 1064/2894 (36.8) |
| 15‐64 | 3255/6004 (54.2) | 1441/2268 (63.5) | 1182/2894 (40.8) |
| ≥65 | 573/6004 (9.5) | 141/2268 (6.2) | 112/2894 (3.9) |
| Missing | 16 | 4 | 7 |
| Sex | |||
| Female | 3159/5975 (52.9) | 1137/2259 (50.3) | 1456/2871 (50.7) |
| Missing | 45 | 13 | 30 |
| Days between onset of symptoms and swabbing | |||
| 0 | 389/6020 (6.5) | 95/2272 (4.2) | 126/2901 (4.3) |
| 1 | 2008/6020 (33.4) | 824/2272 (36.3) | 907/2901 (31.3) |
| 2 | 1589/6020 (26.4) | 663/2272 (29.2) | 899/2901 (31.0) |
| 3 | 934/6020 (15.5) | 348/2272 (15.3) | 539/2901 (18.6) |
| 4‐7 | 1100/6020 (18.3) | 342/2272 (15.1) | 430/2901 (14.8) |
| Seasonal vaccination, 2015/16 | 564/5802 (9.7) | 150/2223 (6.7) | 180/2841 (6.3) |
| Vaccinated <15 d before onset of symptoms | 17 | 0 | 0 |
| Missing | 201 | 49 | 60 |
| Prior season influenza vaccinationb | |||
| Not vaccinated in any season | 3259/3896 (83.6) | 1421/1593 (89.2) | 1481/1635 (90.1) |
| Current season (2015/16) vaccination only | 87/3896 (2.2) | 17/1593 (1.1) | 19/1635 (1.2) |
| Prior (2014/15) season vaccination only | 138/3896 (3.5) | 39/1593 (2.4) | 33/1635 (2.0) |
| Current and prior season vaccination | 412/3896 (10.6) | 116/1593 (7.3) | 102/1635 (6.2) |
| Missing or vaccinated <15 d before onset | 279 | 109 | 69 |
| Seasonal vaccination type | |||
| Not vaccinated | 5255/5819 (90.3) | 2073/2203 (93.3) | 2661/2809 (93.7) |
| Inactivated subunit | 204/5819 (3.5) | 57/2203 (2.6) | 68/2809 (2.4) |
| Inactivated split virion trivalent | 202/5819 (3.5) | 64/2203 (2.9) | 71/2809 (2.5) |
| Adjuvantedc | 60/5819 (1.0) | 6/2203 (0.3) | 6/2809 (0.2) |
| Inactivated cell‐derived subunit | 1/5819 (0.0) | 0/2203 (0.0) | 0/2809 (0) |
| Quadrivalent vaccined | 3/5819 (0.1) | 3/2203 (0.1) | 3/2809 (0.1) |
| Unknown vaccine type | 94/5819 (1.6) | 20/2203 (0.9) | 32/2809 (1.1) |
| Missing vaccination status or date or vaccinated <15 d before onset | 81 | 49 | 60 |
| At least one chronic condition | 1194/5900 (20.2) | 391/2227 (17.6) | 341/2870 (11.9) |
| Missing | 120 | 45 | 31 |
| At least one hospitalisation in the previous 12mo for chronic conditions | 110/5857 (1.9) | 26/2214 (1.2) | 21/2854 (0.7) |
| Missing | 163 | 58 | 47 |
| Belongs to the target group for vaccination | 1648/5931 (27.8) | 544/2236 (24.3) | 434/2873 (15.1) |
| Missing | 89 | 36 | 28 |
| Study sites | |||
| Croatia | 39/6020 (0.6) | 15/2272 (0.7) | 19/2901 (0.7) |
| France | 1471/6020 (24.4) | 508/2272 (22.4) | 1294/2901 (44.6) |
| Germany | 1726/6020 (28.7) | 436/2272 (19.2) | 571/2901 (19.7) |
| Hungary | 593/6020 (9.9) | 54/2272 (2.4) | 112/2901 (3.9) |
| Ireland | 241/6020 (4.0) | 181/2272 (8) | 130/2901 (4.5) |
| Italy | 498/6020 (8.3) | 34/2272 (1.5) | 390/2901 (13.4) |
| Poland | 312/6020 (5.2) | 136/2272 (6.0) | 65/2901 (2.2) |
| Portugal | 186/6020 (3.1) | 111/2272 (4.9) | 11/2901 (0.4) |
| Romania | 80/6020 (1.3) | 61/2272 (2.7) | 0/2901 (0.0) |
| Spain | 286/6020 (4.8) | 447/2272 (19.7) | 165/2901 (5.7) |
| Sweden | 376/6020 (6.2) | 175/2272 (7.7) | 65/2901 (2.2) |
| The Netherlands | 212/6020 (3.5) | 114/2272 (5.0) | 79/2901 (2.7) |
a
Controls for “any influenza” used here (number of controls differs slightly for influenza A(H1N1)pdm09 and B analyses, due to the inclusion criteria).
b
Among patients aged 9 y and over.
c
Includes squalene (MF59), virosome and aluminium phosphate gel adjuvants.
d
Includes Fluenz Tetra (nasal spray) as well as Fluarix Tetra (injectable).